Stay updated with breaking news from Francois Tranquart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
![GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease - Vimarsana News](https://vimarsana.com/images/vimarsana-bigimage.jpg)
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD)
FAIRFIELD (dpa-AFX) - GE Healthcare, the healthcare business of conglomerate General Electric Co. (GE), along with Lantheus Holdings Inc. (LNTH) announced Tuesday that the recent Phase III clinical
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary
GE Healthcare (NYSE:GE) and Lantheus Holdings (NSDQ:LNTH) today announced positive trial results for an investigational radiotracer.